Rybrevant Faspro
Rybrevant Faspro ingredients
| Active ingredient | Strength |
|---|---|
| Amivantamab | 2400 mg/15mL, 2240 mg/14mL, 1600 mg/10mL, 3520 mg/22mL |
| Hyaluronidase (Human Recombinant) | 30000 mg/15mL, 28000 mg/14mL, 20000 mg/10mL, 44000 mg/22mL |
What Rybrevant Faspro is used for
The FDA lists the approved uses on the official label (below). In the EU, amivantamab is approved as Rybrevant for:
Rybrevant is indicated: in combination with lazertinib for the first line treatment of adult patients with advanced non small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations. in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced NSCLC with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI). in combination with carboplatin and pemetrexed for the first line treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations. as monotherapy for treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations, after failure of platinum based therapy.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Rybrevant Faspro
- Generic name
- Amivantamab and hyaluronidase-lpuj (human recombinant)
- Made by
- Janssen Biotech, Inc.
- Forms
- Injection
- Given
- Subcutaneous
- Drug class
- Endoglycosidase
- FDA approval
- Biologic licence (BLA) BLA761433
- On the US market since
- 2025
Official information
- MedlinePlus drug information (search for Amivantamab and hyaluronidase-lpuj (human recombinant))
In India
- Hyaluronidase (human recombinant): 7 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Rybrevant Faspro?
Rybrevant Faspro (Amivantamab and hyaluronidase-lpuj (human recombinant)) is a cancer medicine made by Janssen Biotech, Inc., approved by the US FDA.
What are the ingredients of Rybrevant Faspro?
Rybrevant Faspro contains Amivantamab (2400 mg/15mL, 2240 mg/14mL, 1600 mg/10mL, 3520 mg/22mL); Hyaluronidase (Human Recombinant) (30000 mg/15mL, 28000 mg/14mL, 20000 mg/10mL, 44000 mg/22mL).
Is Rybrevant Faspro approved in Europe?
The same active substance is approved in the EU as Rybrevant.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA